Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ViroGates A/S (VIRO.CO)
Birkerød, DK
ViroGates A/S is a Danish firm specializing in the creation and commercialization of prognostic diagnostic solutions for the medical field. Its flagship product, suPARnostic, is a blood test designed to quantify the soluble urokinase plasminogen activator receptor (suPAR) protein within a patient's circulatory system. This innovative tool empowers hospital emergency rooms to refine their clinical assessments regarding the admission or release of patients with acute medical conditions, thereby contributing to lower healthcare expenditures. Beyond this, ViroGates also supplies several other suPARnostic variations: suPARnostic TurbiLatex, a specialized latex particle-enhanced turbidimetric immunoassay for precise suPAR quantification in specific human plasma samples (K2-EDTA or lithium heparin); the suPARnostic Quick Triage kit, optimized for rapid early warning and patient categorization at the point of care; and suPARnostic ELISA, which delivers comprehensive quantitative readings. The prognostic capabilities of suPAR extend across a broad spectrum of medical conditions, encompassing cardiovascular, renal, oncological, diabetic, hepatic, infectious, respiratory, and rheumatic diseases. Established in 2000, the company maintains its headquarters in Birkerød, Denmark.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.67% | +0.99% | +0.00% | -17.07% | -23.60% | -24.44% | +50.44% | -50.96% | -95.00% | -88.07% | -88.07% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%+8.4% Q1'26: +8.4% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+38.6% ★ Q1'26: +33.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-162.2% Q1'26: -286.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-265.1% Q1'26: -220.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%— Q1'26: +796.8% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+18.5% Q1'26: +39.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.09× Q1'26: -0.37× (vs Q1'25)
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
3.58M
est: 4.20M (-14.8%)
|
5.35M
est: 3.92M (+36.5%)
|
7.66M
est: 8.34M (-8.2%)
|
15.20M
est: 16.43M (-7.5%)
|
6.99M
est: 48.74M (-85.7%)
|
4.90M
est: 87.93M (-94.4%)
|
5.31M
est: 145.13M (-96.3%)
|
190.96M
190.96M – 190.96M
+31.6% YoY
|
| EBITDA |
-19.60M
est: -3.95M (-396.3%)
|
-19.50M
est: -3.68M (-429.4%)
|
-18.57M
est: -7.83M (-137.1%)
|
-10.59M
est: -15.43M (+31.4%)
|
-12.48M
est: -45.79M (+72.7%)
|
-14.52M
est: -82.60M (+82.4%)
|
-14.07M
est: -136.33M (+89.7%)
|
-179.38M
-179.38M – -179.38M
-31.6% YoY
|
| EBIT |
-19.71M
est: -3.96M (-398.0%)
|
-19.70M
est: -3.69M (-433.4%)
|
-18.77M
est: -7.85M (-139.0%)
|
-10.76M
est: -15.47M (+30.4%)
|
-12.52M
est: -45.90M (+72.7%)
|
-14.52M
est: -82.80M (+82.5%)
|
-14.07M
est: -136.67M (+89.7%)
|
-179.82M
-179.82M – -179.82M
-31.6% YoY
|
| Net Income |
-18.80M
est: -28.00M (+32.9%)
|
-18.74M
est: -36.27M (+48.3%)
|
-17.66M
est: -29.90M (+40.9%)
|
-9.65M
est: -19.88M (+51.5%)
|
-12.10M
est: 12.28M (-198.5%)
|
-14.35M
est: 67.54M (-121.2%)
|
-10.40M
est: 142.45M (-107.3%)
|
158.89M
158.89M – 158.89M
+11.5% YoY
|
| SGA |
17.34M
est: 9.18M (+88.9%)
|
18.12M
est: 8.56M (+111.6%)
|
18.64M
est: 18.21M (+2.3%)
|
12.92M
est: 35.88M (-64.0%)
|
11.93M
est: 106.46M (-88.8%)
|
12.46M
est: 162.20M (-92.3%)
|
8.95M
est: 267.71M (-96.7%)
|
352.25M
352.25M – 352.25M
+31.6% YoY
|
| EPS |
-4.78
est: -4.20 (-13.7%)
|
-4.69
est: -5.44 (+13.8%)
|
-4.32
est: -4.49 (+3.7%)
|
-2.29
est: -2.98 (+23.3%)
|
-3.49
est: 1.84 (-289.4%)
|
-2.15
est: 8.55 (-125.1%)
|
-1.32
est: 18.04 (-107.3%)
|
20.12
20.12 – 20.12
+11.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jakob Knudsen | Chief Executive Officer | 2M | male |
| Jesper Eugen-Olsen | Co-Founder & Chief Scientific Officer | — | — |
| Josephine Baum Jorgensen | Chief Financial Officer | — | female |
| May Britt Dyvelkov | Vice President of Accounting | — | female |
| Thomas Krarup | Vice President of Global Sales & Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VIRO.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
